251 related articles for article (PubMed ID: 16476686)
21. Final report on the safety assessment of polyethylene.
Int J Toxicol; 2007; 26 Suppl 1():115-27. PubMed ID: 17365139
[TBL] [Abstract][Full Text] [Related]
22. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety.
Nohynek GJ; Lademann J; Ribaud C; Roberts MS
Crit Rev Toxicol; 2007 Mar; 37(3):251-77. PubMed ID: 17453934
[TBL] [Abstract][Full Text] [Related]
23. Human health safety evaluation of cosmetics in the EU: a legally imposed challenge to science.
Pauwels M; Rogiers V
Toxicol Appl Pharmacol; 2010 Mar; 243(2):260-74. PubMed ID: 20006634
[TBL] [Abstract][Full Text] [Related]
24. Applications and implications of nanotechnologies for the food sector.
Chaudhry Q; Scotter M; Blackburn J; Ross B; Boxall A; Castle L; Aitken R; Watkins R
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2008 Mar; 25(3):241-58. PubMed ID: 18311618
[TBL] [Abstract][Full Text] [Related]
25. Is New Zealand's regulation of nanomedical products adequate?
Moore J
J Law Med; 2011 Sep; 19(1):112-27. PubMed ID: 21988014
[TBL] [Abstract][Full Text] [Related]
26. Safety evaluation of superabsorbent baby diapers.
Kosemund K; Schlatter H; Ochsenhirt JL; Krause EL; Marsman DS; Erasala GN
Regul Toxicol Pharmacol; 2009 Mar; 53(2):81-9. PubMed ID: 18992296
[TBL] [Abstract][Full Text] [Related]
27. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
28. Final report on the safety assessment of human placental protein, hydrolyzed human placental protein, human placental enzymes, human placental lipids, human umbilical extract, placental protein, hydrolyzed placental protein, placental enzymes, placental lipids, and umbilical extract.
Nair B; Elmore AR;
Int J Toxicol; 2002; 21 Suppl 1():81-91. PubMed ID: 12042062
[TBL] [Abstract][Full Text] [Related]
29. Lead contamination of inexpensive seasonal and holiday products.
Weidenhamer JD
Sci Total Environ; 2009 Mar; 407(7):2447-50. PubMed ID: 19095292
[TBL] [Abstract][Full Text] [Related]
30. A survey of polycyclic musks in selected household commodities from the United States.
Reiner JL; Kannan K
Chemosphere; 2006 Feb; 62(6):867-73. PubMed ID: 16309730
[TBL] [Abstract][Full Text] [Related]
31. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
Zolnik BS; Sadrieh N
Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
[TBL] [Abstract][Full Text] [Related]
32. [Guidelines for evaluation of the safety of nanomaterials].
Onishchenko GG; Archakov AI; Bessonov VV; Bokit'ko BG; Gintsburg AL
Gig Sanit; 2007; (6):3-10. PubMed ID: 18161181
[TBL] [Abstract][Full Text] [Related]
33. [Health risks of engineered nanomaterials and nanotechnologies].
Savolainen K; Vainio H
Duodecim; 2011; 127(11):1097-104. PubMed ID: 21755801
[TBL] [Abstract][Full Text] [Related]
34. Nanodermatology: a bright glimpse just beyond the horizon - part I.
Nasir A
Skin Therapy Lett; 2010 Sep; 15(8):1-4. PubMed ID: 20844848
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnology in cosmetic products.
Epstein HA
Skinmed; 2011; 9(2):109-10. PubMed ID: 21548515
[TBL] [Abstract][Full Text] [Related]
36. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2007; 26 Suppl 2():79-112. PubMed ID: 17613133
[TBL] [Abstract][Full Text] [Related]
37. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications.
Pederson LL; Nelson DE
Nicotine Tob Res; 2007 May; 9(5):525-34. PubMed ID: 17454709
[TBL] [Abstract][Full Text] [Related]
38. Limits and prospects of the "incremental approach" and the European legislation on the management of risks related to nanomaterials.
Franco A; Hansen SF; Olsen SI; Butti L
Regul Toxicol Pharmacol; 2007 Jul; 48(2):171-83. PubMed ID: 17509740
[TBL] [Abstract][Full Text] [Related]
39. A perspective on the safety of cosmetic products: a position paper of the American Council on Science and Health.
Ross G
Int J Toxicol; 2006; 25(4):269-77. PubMed ID: 16815815
[TBL] [Abstract][Full Text] [Related]
40. Nanomaterial health effects part 3: conclusion--hazardous issues and the precautionary principle.
Kanarek MS
WMJ; 2007 Feb; 106(1):16-9. PubMed ID: 17393752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
